Brooklyn ImmunoTherapeutics Receivables

Brooklyn ImmunoTherapeutics's receivables stands at $940K as of December 2025. That compares with $67K in the prior-year period — up 1306.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Brooklyn ImmunoTherapeutics reported $940K in receivables versus $67K a year earlier — a 1306.8% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $67K in the prior-year period — up 1306.8% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Brooklyn ImmunoTherapeutics's receivables evolved across reporting periods, while the comparison chart places BTX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Telecommunications, receivables is commonly used to spot outliers. Brooklyn ImmunoTherapeutics's reading of $940K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.